Glioblastoma Market: Epidemiology, Therapies, Companies, DelveInsight | Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CN

Glioblastoma emerging therapies, such as Avastin, Temodar/Temodal, ITI-1000 (pp65 DC Vaccine), VBI-1901, Selinexor (KPT-330), Trans Sodium Crocetinate, Ofranergene obadenovec (VB-111), and others, are expected to boost the Glioblastoma Market in the upcoming years.

DelveInsight has launched a new report on "Glioblastoma - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Glioblastoma, historical and forecasted epidemiology as well as the Glioblastoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Glioblastoma market report @ https://www.delveinsight.com/report-store/glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Glioblastoma Market Report:

According to DelveInsight, the Glioblastoma market is projected to witness significant growth between 2024 and 2034, driven by the introduction of new treatment options and an increasing number of diagnosed cases.
In the United States, the gender-specific diagnosed incidence of glioblastoma in 2021 showed a higher number of cases among males, with approximately 7,705 cases reported, compared to fewer cases in the female population.
In December 2024, Kazia Therapeutics was notified by the FDA that its brain cancer drug, paxalisib, is unlikely to receive accelerated approval. The agency cited that the 3.8-month overall survival benefit seen in the Phase II/III GBM-AGILE trial does not fulfill the requirements for such approval.
On October 15, 2024, the FDA granted Fast Track designation to Lantern Pharma's LP-184, a small-molecule alkylating agent for glioblastoma (GBM). LP-184, which works by inducing DNA damage to kill tumor cells, is currently being evaluated in a Phase 1a trial for various solid tumors, including GBM. The Fast Track status is intended to speed up its development and review, addressing the urgent need for new treatments for aggressive brain tumors like GBM.
Prominent companies contributing to this market include Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai, Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, Forma Therapeutics, VBI Vaccines, TME Pharma, and others.
Promising Glioblastoma therapies include Dazukibart (PF-06823859), and others.

Glioblastoma Overview

Glioblastoma is the most common type of primary tumor affecting the central nervous system (CNS), particularly in adults. Despite advancements in diagnostics and the development of new treatments, its overall prognosis remains poor. These tumors typically form in the cerebrum, a part of the forebrain responsible for complex functions like speech and emotional regulation. The exact cause of glioblastoma is still unknown. In some instances, it may arise from the malignant transformation of pre-existing low-grade astrocytomas, while in others, it can appear spontaneously without any prior tumor (de novo).

Glioblastoma Market Outlook

Treating glioblastoma is particularly difficult because different tumor cells may respond variably to therapies-some are sensitive while others remain unaffected. As a result, treatment typically involves a multimodal approach, often combining surgery, chemotherapy, radiation therapy, or stereotactic radiosurgery. Additional treatments, such as chemotherapy or radiation, may follow surgery to enhance outcomes.

Surgical intervention is usually the first step, aimed at confirming the diagnosis, reducing intracranial pressure, and removing as much of the tumor as safely possible. This approach, known as "maximum safe resection," focuses on excising the tumor without causing permanent neurological damage.

Notably, the glioblastoma market is seeing innovation with emerging therapies such as gene therapy candidates like Ofranergene obadenovec (VB-111) from VBL Therapeutics, and several immunotherapy/vaccine-based treatments including VBI-1901, AV-Glioblastoma-1, ITI-1000 (pp65 DC Vaccine), and Tasadenoturev (DNX-2401), being developed by companies like VBI Vaccines, Aivita Biomedical, Immunomic Therapeutics, and DNAtrix.

The treatment pipeline for glioblastoma features a number of promising therapies in mid-to-late stages of development. Key players driving this innovation include Kazia Therapeutics with Paxalisib (GDC-0084), Laminar Pharmaceuticals with LAM561, and DNAtrix with Tasadenoturev (DNX-2401), all of which are expected to significantly influence the future market landscape.

Discover how the Glioblastoma market is rising in the coming years @ https://www.delveinsight.com/sample-request/glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Glioblastoma Emerging Drugs:

Ofranergene obadenovec (VB-111): VBL Therapeutics
Trans Sodium Crocetinate: Diffusion Pharmaceuticals
Selinexor (KPT-330): Karyopharm Therapeutics
VBI-1901: VBI Vaccines
ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics

Glioblastoma Marketed Drugs
Avastin: Genentech
Temodar/Temodal: Merck

Scope of the Glioblastoma Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Glioblastoma Companies: Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai and Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, Forma Therapeutics, VBI Vaccines, TME Pharma, and others
Key Glioblastoma Therapies: Avastin, Temodar/Temodal, ITI-1000 (pp65 DC Vaccine), VBI-1901, Selinexor (KPT-330), Trans Sodium Crocetinate, Ofranergene obadenovec (VB-111), and others
Glioblastoma Therapeutic Assessment: Glioblastoma current marketed and Glioblastoma emerging therapies
Glioblastoma Market Dynamics: Glioblastoma market drivers and Glioblastoma market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Glioblastoma Unmet Needs, KOL's views, Analyst's views, Glioblastoma Market Access and Reimbursement

To know what's more in our Glioblastoma report, visit https://www.delveinsight.com/report-store/glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Glioblastoma Market Report:
Glioblastoma market report covers a descriptive overview and comprehensive insight of the Glioblastoma Epidemiology and Glioblastoma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Glioblastoma market report provides insights into the current and emerging therapies.
The Glioblastoma market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Glioblastoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Glioblastoma market.

Got queries? Click here to know more about the Glioblastoma market Landscape https://www.delveinsight.com/sample-request/glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Glioblastoma Patient Share (%) Overview at a Glance
5. Glioblastoma Market Overview at a Glance
6. Glioblastoma Disease Background and Overview
7. Glioblastoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Glioblastoma
9. Glioblastoma Current Treatment and Medical Practices
10. Unmet Needs
11. Glioblastoma Emerging Therapies
12. Glioblastoma Market Outlook
13. Country-Wise Glioblastoma Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Glioblastoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Glioblastoma Market Outlook 2034 https://www.delveinsight.com/report-store/glioblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Glioblastoma Pipeline Insights, DelveInsight

"Glioblastoma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Glioblastoma market. A detailed picture of the Glioblastoma pipeline landscape is provided, which includes the disease overview and Glioblastoma treatment guidelines.

Contact Info:

Kritika Rehani, Team Leader Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.